Definium Therapeutics Stock Performance
as on October 17, 2026 at 2:16 pm IST
Day's Low
Day's High
$32.02$34.00
0.25%
Downside
5.92%
Upside
52 Week's Low
52 Week's High
100.00%
Downside
-100.00%
Upside
Definium Therapeutics share price movements today
- Previous Close
- $34.26
- Open
- $34.00
- Volume
- 1.3M
- Market Cap
- $4.6B
- Day's Low - High
- $32.02 - $34.00
Definium Therapeutics Historical Returns
- 1 Month Return
- -17.01 %
- 3 Month Return
- -27.52 %
- 1 Year Return
- 0 %
- 3 Year Return
- 0 %
- 5 Year Return
- 0 %
Definium Therapeutics Stock Fundamentals & Key Indicators
Check Definium Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$4.6B
EPS (TTM)
-3.44
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-9.96
Industry PE ratio
-11.21
PEG Ratio
0.13
EBITDA
-339.7M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-85.23%
Definium Therapeutics vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Definium Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| StrongBuy | $4.6B | NA | -9.96 | 0.00% | 0.00% | |
| Neutral | $94.4B | -32.76% | -29.64 | -12.57% | 0.00% | |
| StrongBuy | $128.9B | 174.93% | 29.37 | 86.04% | 0.00% | |
| Buy | $80.1B | 42.93% | 19.01 | 84.86% | 0.46% |
Analyst Recommendation on Definium Therapeutics Stock
Based on 10 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Definium Therapeutics. Average target price of $73.6
Definium Therapeutics Share Price Target
Get share price movements and forecasts by analysts on Definium Therapeutics.
Current Price
$32.1
Analyzed by
10 Analysts
High
$90
Low
$65
Definium Therapeutics target price $0, a slight upside of 0% compared to current price of $32.1. According to 10 analysts rating.
Indian Investors' Interest in Definium Therapeutics Stock
Search interest for Definium Therapeutics Stock has decreased by -34% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Definium Therapeutics Quarterly Profit & Loss
All numbers in Millions USD
Definium Therapeutics Annual Profit & Loss
All numbers in Millions USD
Definium Therapeutics Quarterly Cash Flow
All numbers in Millions USD
Definium Therapeutics Annual Cash Flow
All numbers in Millions USD
Definium Therapeutics News & Key Events
Today's Timeline - 14 September
Mon, 06:00 PM
-Definium reports positive Phase 3 results for DT120, meeting primary and secondary efficacy endpoints in generalized anxiety disorder.
Mon, 10:00 PM
-BofA raises Definium's price target to $91, citing positive Phase 3 results for DT120 in generalized anxiety disorder.
Tue, 01:30 AM
-Oppenheimer raises Definium's price target to $75, maintaining an Outperform rating after positive Phase 3 results.
Insights on Definium Therapeutics
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 years, DFTX stock has moved up by 991.8%
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, DFTX has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECTAgainst Peers
In the last 1 year, Moderna, Inc. Common Stock has given 738.2% return, outperforming this stock by 603.0%
About Definium Therapeutics
| Organisation | Definium Therapeutics |
| Headquarters | One World Trade Center, New York, NY, 10007, US |
| Industry | Biotechnology |
| CEO | Robert Barrow |
Key Management of Definium Therapeutics
Name | Title |
|---|---|
Mr. Leonard Latchman | Co-Founder |
Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations |
Ms. Gitanjali Jain Ogawa | VP & Head of Investor Relations |
Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary |
Ms. Beth Calitri | Vice President of Corporate Communications |
Mr. Robert Barrow | CEO & Director |
Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer |
Ms. Stephanie Fagan M.S. | Chief Corporate Affairs Officer |
Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer |
Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor |
FAQs
What is Definium Therapeutics share price today?
Definium Therapeutics share price today is $32.10 as on at the close of the market. Definium Therapeutics share today touched a day high of $34.00 and a low of $32.02.
What is the 52 week high and 52 week low for Definium Therapeutics share?
Definium Therapeutics share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Definium Therapeutics stock price today i.e. is closed at $32.10,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.
What is Definium Therapeutics's market capitalisation today?
Definium Therapeutics market capitalisation is $0.00T as on .
How to invest in Definium Therapeutics Stock (DFTX) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Definium Therapeutics on INDmoney app. Click on Buy button.
What is the minimum amount required to buy Definium Therapeutics Stock (DFTX) from India?
Indian investors can start investing in Definium Therapeutics (DFTX) shares with as little as ₹94.95999908447266 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Definium Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Definium Therapeutics share’s latest price of $32.10 as on October 17, 2026 at 8:46 am IST, you will get 0.3115 shares of Definium Therapeutics. Learn more about
fractional shares .